Tag - IMUX

Developments

Immunic posts positive Phase 1b results in celiac disease

Immunic (NASDAQ:IMUX) announced positive results from the part C portion of its Phase 1 clinical trial of IMU-856 in patients with celiac disease. The company believes that this data set provides initial clinical proof...

May 4, 2023

Markets

SVB Leerink starts Immunic at OP, PT $45

SVB Leerink launched coverage of Immunic (NASDAQ:IMUX) with an “outperform” rating and $45 price target. The stock closed at $18.87 on Oct. 1. Immunic is focused on development of novel therapeutics for the treatment of...

October 2, 2020

Developments

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

The first patients have been enrolled in an investigator-sponsored Phase 2 study evaluating Immunic Therapeutics‘ (NASDAQ:IMUX) IMU-838 for the treatment of COVID-19. IMU-838 is a selective immune modulator that...

July 27, 2020

Markets

Roth starts Immunic at buy; PT $44

Roth Capital Partners launched coverage of Immunic (NASDAQ:IMUX) with a “buy” rating and $44 price target. The stock closed at $5.74 on March 24. Immunic is focused on developing innovative new modulators of the immune...

March 25, 2020

Developments

Immunic completes enrollment for Phase 2 MS trial

Immunic (NASDAQ:IMUX) completed enrollment for its Phase 2 trial assessing IMU-838 for the treatment of relapsing-remitting multiple sclerosis (RRMS). IMU-838 is a selective immune modulator that blocks the enzyme...

October 11, 2019

Markets

Ladenburg starts Immunic at buy; PT $50

Ladenburg Thalmann initiated coverage of Immunic (NASDAQ:IMUX) with a “buy” rating and $50 price target. The stock closed at $14.30 on April 22.

April 23, 2019

Tag - IMUX

Immunic posts positive Phase 1b results in celiac disease

SVB Leerink starts Immunic at OP, PT $45

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

Roth starts Immunic at buy; PT $44

Immunic completes enrollment for Phase 2 MS trial

Ladenburg starts Immunic at buy; PT $50

General

More